# A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

> **NCT06555419** · PHASE1 · RECRUITING · sponsor: **Biogen** · enrollment: 58 (estimated)

## Conditions studied

- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** Nusinersen
- **DEVICE:** ThecaFlex DRx System

## Key facts

- **NCT ID:** NCT06555419
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2027-06-25
- **Final completion:** 2027-06-25
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06555419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06555419, "A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06555419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*